ESR1 and ovarian cancer: In this study, we have demonstrated that 25HC is able 1) to activate ERα, possibly by binding directly as an agonistic ligand, 2) to up-regulate diverse estrogen target genes, 3) to modulate ERα and Cyclin D1 protein levels and 4) to stimulate growth effects in breast and ovarian cancer cells.